News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE), GlaxoSmithKline (GSK) and NovaDigm Therapeutics ' Vaccine for Staph More Lethal Than Skin Cancer Tested



9/17/2012 8:01:15 AM

A new wave of experimental vaccines is the medical community’s latest hope against a powerful staph infection that kills more people in the U.S. than skin cancer and costs as much as $8 billion a year to treat. Pfizer Inc. (PFE) and GlaxoSmithKline Plc (GSK), two of the world’s biggest drugmakers, and NovaDigm Therapeutics Inc., a closely held biotechnology company, are each testing novel vaccines to halt methicillin-resistant Staphylococcus aureus, or MRSA, long a dangerous infection in hospitals and nursing homes and which is now increasingly finding its way into daycare centers, schools and prisons.

Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES